Screener

Eligibility screening

Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma

Sponsored by TransThera Sciences (Nanjing), Inc.Study detailsClinicalTrials.gov

19 US sites in CA, FL, IL, MA +9

Before we begin

Who are you filling this out for?

Your answer affects how the questions are phrased.